Kobayashi, I.S.; Viray, H.; Rangachari, D.; Kobayashi, S.S.; Costa, D.B.
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells 2021, 10, 3561.
https://doi.org/10.3390/cells10123561
AMA Style
Kobayashi IS, Viray H, Rangachari D, Kobayashi SS, Costa DB.
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells. 2021; 10(12):3561.
https://doi.org/10.3390/cells10123561
Chicago/Turabian Style
Kobayashi, Ikei S., Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, and Daniel B. Costa.
2021. "EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios" Cells 10, no. 12: 3561.
https://doi.org/10.3390/cells10123561
APA Style
Kobayashi, I. S., Viray, H., Rangachari, D., Kobayashi, S. S., & Costa, D. B.
(2021). EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells, 10(12), 3561.
https://doi.org/10.3390/cells10123561